Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors; it is characterized by muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids (e.g., prednisone), and short- and long-term immunosuppressants (e.g., mycophenolate mofetil, azathioprine) are the most prescribed agents to manage the symptoms of MG. However, the MG pipeline is starting to bring therapies with unique mechanisms of action to the market, highlighted by the FDA’s approval of eculizumab (Alexion / AstraZeneca’s Soliris) in 2017, efgartigimod alfa (Argenx’s Vyvgart) in 2021, and ravulizumab (Alexion / AstraZeneca’s Ultomiris) in 2022. As the treatment landscape for MG continues to evolve, this report offers insight based on real-world claims data into prescribing trends for MG to help new players understand current treatment practices and to define the market niche for their emerging products.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MG patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MG patients?
- How have the new MG therapies been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of MG patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of MG patients are treated with monotherapy versus combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Alexion, Argenx, AstraZeneca
Key drugs: Soliris, Ultomiris, Vyvgart, pyridostigmine, prednisone, azathioprine, mycophenolate mofetil, rituximab, intravenous immunoglobulin
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Myasthenia Gravis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Myasthenia Gravis US March 2023
- Treatment Algorithms CDA Myasthenia Gravis 2023 Dashboard
Rafael Widjajahakim, M.S., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. Prior to joining the company, he was a clinical research coordinator at University of Massachusetts Medical School. He received his master of science degree in clinical investigation from Boston University and his bachelor of science degree in biology from Suffolk University.